bioAffinity technologies' stock has experienced a significant surge, with some outlets reporting increases of over 100% in recent months. The surge may be driven by increased demand for the company's CyPath Lung test, which has seen test volume more than triple in the second quarter of 2026, as well as a lung cancer study initiative. However, there is some uncertainty about the company's performance, with one report mentioning a rocky third quarter for bioAffinity.